Evaluating the clinical utility of the patient-identified most bothersome symptom measure from PROMISE-2 for research in migraine prevention.

Lipton RB, Goadsby PJ, Dodick DW, McGinley JS, Houts CR, Wirth RJ, Kymes S, Ettrup A, Østerberg O, Cady R, Ashina M, Buse DC. Evaluating the clinical utility of the patient-identified most bothersome symptom measure from PROMISE-2 for research in migraine prevention. Headache. 2022 Apr 25.

View in: PubMed